Literature DB >> 6232143

Studies on 18F-labeled pyrimidines. II. Metabolic investigation of 18F-5-fluorouracil, 18F-5-fluoro-2'-deoxyuridine and 18F-5-fluorouridine in rats.

K Ishiwata, T Ido, K Kawashima, M Murakami, T Takahashi.   

Abstract

18F-labeled 5-fluorouracil(FUra), 5-fluoro-2'-deoxyuridine(FdUrd), and 5-fluorouridine ( FUrd ) were synthesized with high radiochemical purities. The 18F-labeled pyrimidines were injected into rats. The metabolites in serum, bile, and urine were analyzed up to 2 h after administration by radio-high performance liquid chromatography (HPLC). The blood clearance of three pyrimidines was very rapid. In the serum the nucleosides and base disappeared very rapidly with a biological half-life of about 2 min and most of them had disappeared by 60 min. The metabolites in the urine were similar to those in the serum. In the bile pyrimidine nucleosides and base were not detected. 18F- was found in the metabolites. Our results explain the high uptakes in the kidney and liver in biodistribution studies of the 18F-labeled pyrimidines.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6232143     DOI: 10.1007/bf00251469

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  7 in total

1.  Studies on fluorinated pyrimidines. IX. The degradation of 5-fluorouracil-6-C14.

Authors:  K L MUKHERJEE; C HEIDELBERGER
Journal:  J Biol Chem       Date:  1960-02       Impact factor: 5.157

2.  Metabolic trapping as a principle of oradiopharmaceutical design: some factors resposible for the biodistribution of [18F] 2-deoxy-2-fluoro-D-glucose.

Authors:  B M Gallagher; J S Fowler; N I Gutterson; R R MacGregor; C N Wan; A P Wolf
Journal:  J Nucl Med       Date:  1978-10       Impact factor: 10.057

3.  Distribution of 18F-5-fluorouracil in tumor-bearing mice and rats.

Authors:  J Shani; W Wolf; T Schlesinger; H L Atkins; P R Bradley-Moore; V Casella; J S Fowler; D Greenberg; T Ido; R M Lambrecht; R MacGregor; C Mantescu; R Neirinckx; P Som; A P Wolf; I Wodinsky; K Meaney
Journal:  Int J Nucl Med Biol       Date:  1978-03

4.  The synthesis of 18 F-5-fluorouracil. VII.

Authors:  J S Fowler; R D Finn; R M Lambrecht; A P Wolf
Journal:  J Nucl Med       Date:  1973-01       Impact factor: 10.057

5.  An improved synthesis of 18F-5-fluorouracil.

Authors:  E N Vine; D Young; W H Vine; W Wolf
Journal:  Int J Appl Radiat Isot       Date:  1979-07

6.  Dosimetry and preliminary human studies of 18F-5-fluorouracil.

Authors:  J Shani; D Young; T Schlesinger; J K Siemsen; R T Chlebowski; J R Bateman; W Wolf
Journal:  Int J Nucl Med Biol       Date:  1982

7.  Studies on 18F-labeled pyrimidines. Tumor uptakes of 18F-5-fluorouracil, 18F-5-fluorouridine, and 18F-5-fluorodeoxyuridine in animals.

Authors:  Y Abe; H Fukuda; K Ishiwata; S Yoshioka; K Yamada; S Endo; K Kubota; T Sato; T Matsuzawa; T Takahashi; T Ido
Journal:  Eur J Nucl Med       Date:  1983
  7 in total
  6 in total

Review 1.  Fluorinated tracers for imaging cancer with positron emission tomography.

Authors:  Olivier Couturier; André Luxen; Jean-François Chatal; Jean-Philippe Vuillez; Pierre Rigo; Roland Hustinx
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-07-06       Impact factor: 9.236

2.  An optimized synthesis of 18F-labelled 5-fluorouracil and a reevaluation of its use as a prognostic agent.

Authors:  G W Visser; G C Gorree; B J Braakhuis; J D Herscheid
Journal:  Eur J Nucl Med       Date:  1989

3.  Brain tumor accumulation and plasma pharmacokinetic parameters of 2'-deoxy-5-18F-fluorouridine.

Authors:  K Ishiwata; Y Tsurumi; M Kameyama; K Sato; R Iwata; T Takahashi; T Ido; T Yoshimoto
Journal:  Ann Nucl Med       Date:  1993-08       Impact factor: 2.668

4.  Metabolic changes of glioma following chemotherapy: an experimental study using four PET tracers.

Authors:  K Sato; M Kameyama; K Ishiwata; R Katakura; T Yoshimoto
Journal:  J Neurooncol       Date:  1992-09       Impact factor: 4.130

5.  Studies on 18F-labeled pyrimidines III. Biochemical investigation of 18F-labeled pyrimidines and comparison with 3H-deoxythymidine in tumor-bearing rats and mice.

Authors:  K Ishiwata; T Ido; Y Abe; T Matsuzawa; M Murakami
Journal:  Eur J Nucl Med       Date:  1985

6.  Clinical application of 18F-FUdR in glioma patients--PET study of nucleic acid metabolism.

Authors:  M Kameyama; K Ishiwata; Y Tsurumi; J Itoh; K Sato; R Katakura; T Yoshimoto; J Hatazawa; M Ito; T Ido
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.